Trial Profile
A Phase 2 Study of Abemaciclib in Patients With Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer, Non-small Cell Lung Cancer, or Melanoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Abemaciclib (Primary)
- Indications Advanced breast cancer; Brain metastases; HER2 negative breast cancer; HER2 positive breast cancer; Malignant melanoma; Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 12 Jul 2020 Primary endpoint (Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR): Objective Intracranial Response Rate (OIRR)) has not been met as per results published in the Clinical Cancer Research
- 12 Jul 2020 Results published in the Clinical Cancer Research
- 17 Dec 2019 Status changed from active, no longer recruiting to completed.